Company Expects to Exceed Previously Announced Guidance Across All Key Metrics; Provides Full Year 2021 Guidance and Updates Long-Term Targets
CareScheduler Automates Vaccine Scheduling, Consent Collection, Registry Reporting and Patient Outreach; Enables Pharmacies to Efficiently Administer COVID-19 Vaccine
Omnicell announced its intent to enter a new partnership with Guy’s and St Thomas’ NHS Foundation Trust, London to develop technology-enabled inventory optimization and intelligence services.
Owensboro Health, a long-term sole source partner, will expand their medication management automation platform to central pharmacy operations with Omnicell’s Central Pharmacy Dispensing Service.
EnlivenHealth™ launches CareScheduler solution to enable pharmacies to provide hands-free scheduling, consent and registry reporting for COVID-19 vaccine, and announces results of COVID-19 vaccine survey
Omnicell's Winter 2020 release delivers innovation to support the Autonomous Pharmacy to zero-error medication management.
Omnicell will provide Allegheny Health Network (AHN) with central pharmacy dispensing and medication management solutions at the point of care across the network’s 13 hospital locations in western Pennsylvania.
Omnicell, Inc. (NASDAQ: OMCL) announces results for its third quarter ended September 30, 2020.
Lehigh Valley Health Network (LVHN) will be leveraging Omnicell’s industry-leading medication management platform of solutions to enhance efficiency, control, and safety of medication management.
Memorial Hospital at Gulfport, Mississippi has chosen the Company’s Central Pharmacy Dispensing Service, part of the industry-leading medication management platform, to support their pharmacy operations.
Omnicell announced it is launching EnlivenHealth™, a division dedicated to enabling retail pharmacies and health plans to improve patient outcomes while reducing costs through innovative Software-as-a-Service (SaaS) technology solutions.
Omnicell, Inc. (NASDAQ: OMCL) announced it has completed the previously announced acquisition of Pharmaceutical Strategies Group’s (PSG) 340B Link business.
Maryland-based Peninsula Regional Medical Center has chosen Omnicell's industry-leading medication management platform to support their in-house sterile compounding operations.
Omnicell, Inc. (NASDAQ: OMCL) announced it has entered into a definitive agreement with Pharmaceutical Strategies Group (PSG) to acquire its 340B Link business.
Omnicell, Inc. (NASDAQ: OMCL) announces results for its second quarter ended June 30, 2020.
Omnicell announced that it continues to deliver innovation to support the fully Autonomous Pharmacy through the launch of Omnicell One™, a predictive pharmacy intelligence solution that will be generally available in August 2020.